Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
BMC Public Health ; 22(1): 606, 2022 03 29.
Article in English | MEDLINE | ID: mdl-35351061

ABSTRACT

BACKGROUND: Epidemiological data from Mexico have documented an increase in heroin use in the last decade. However, there is no comprehensive care strategy for heroin users, especially those who have been accused of a crime. The objective of this study was to describe the heroin and methadone use of intravenous heroin users of both sexes who have been in jail, to offer evidence for the formulation of health policy. METHODS: This study used an ethnographic approach, with open-ended interviews carried out from 2014 to the present. Heroin users of both sexes attending a private methadone clinic in Mexico City were invited to participate. The sample was non-probabilistic. All interviews were audiotaped and transcribed, and narratives were analyzed using thematic analysis. RESULTS: Participants in this study were 33 users of heroin, two of them women, who had been in prison. They ranged in age from 33 to 62 years, had used heroin for a period of 13-30 years, and were from three states: Michoacan, Oaxaca, and Mexico City. Three principal categories of analysis were structured: 1. Pilgrimage for help (dynamics of the drama of suffering, pain, and time through health care spaces); 2) methadone use as self-care; and 3) accessibility to methadone treatment. The impossibility of access to methadone treatment is a condition which motivates users in their journey. The dynamics of methadone use are interpreted as a form of self-care and care to avoid substance use. Reducing the psychological, physical, and harmful effects of the substance allows them to perform daily activities. The inability to access treatment leads to a significant effect on users who experience structural violence. CONCLUSION: Compassionate methadone treatment and holistic attention should be considered as a way to meet patients' needs and mitigate their suffering, based on public health policy that allows for human rights-based care.


Subject(s)
Compassionate Use Trials , Heroin Dependence , Adult , Female , Heroin Dependence/drug therapy , Heroin Dependence/epidemiology , Heroin Dependence/psychology , Humans , Male , Methadone/therapeutic use , Mexico/epidemiology , Middle Aged , Violence
2.
Am J Psychiatry ; 166(11): 1269-77, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19651710

ABSTRACT

OBJECTIVE: Cocaine dependence is associated with severe medical, psychiatric, and social morbidity, but no pharmacotherapy is approved for its treatment in the United States. The atypical antiepileptic vigabatrin (gamma-vinyl gamma-aminobutyric acid [GABA]) has shown promise in animal studies and open-label trials. The purpose of the present study was to assess the efficacy of vigabatrin for short-term cocaine abstinence in cocaine-dependent individuals. METHOD: Participants were treatment seeking parolees who were actively using cocaine and had a history of cocaine dependence. Subjects were randomly assigned to a fixed titration of vigabatrin (N=50) or placebo (N=53) in a 9-week double-blind trial and 4-week follow-up assessment. Cocaine use was determined by directly observed urine toxicology testing twice weekly. The primary endpoint was full abstinence for the last 3 weeks of the trial. RESULTS: Full end-of-trial abstinence was achieved in 14 vigabatrin-treated subjects (28.0%) versus four subjects in the placebo arm (7.5%). Twelve subjects in the vigabatrin group and two subjects in the placebo group maintained abstinence through the follow-up period. The retention rate was 62.0% in the vigabatrin arm versus 41.5% in the placebo arm. Among subjects who reported prestudy alcohol use, vigabatrin, relative to placebo, was associated with superior self-reported full end-of-trial abstinence from alcohol (43.5% versus 6.3%). There were no differences between the two groups in drug craving, depressed mood, anxiety, or Clinical Global Impression scores, and no group differences in adverse effects emerged. CONCLUSIONS: This first randomized, double-blind, placebo-controlled trial supports the safety and efficacy of short-term vigabatrin treatment of cocaine dependence.


Subject(s)
Anticonvulsants/therapeutic use , Cocaine-Related Disorders/drug therapy , Mexican Americans/statistics & numerical data , Vigabatrin/therapeutic use , Adult , Alcoholism/rehabilitation , Alcoholism/therapy , Cocaine-Related Disorders/rehabilitation , Combined Modality Therapy , Double-Blind Method , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Male , Mexican Americans/legislation & jurisprudence , Mexican Americans/psychology , Placebos , Severity of Illness Index , Substance Abuse Detection/statistics & numerical data , Temperance/statistics & numerical data , Treatment Outcome , Urban Population
3.
Arch Ophthalmol ; 124(9): 1257-62, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16966620

ABSTRACT

OBJECTIVE: To evaluate the ocular safety of short-term use of vigabatrin to treat cocaine and/or methamphetamine addiction. METHODS: Individuals who were actively using cocaine and/or methamphetamine were eligible for enrollment. Enrolled subjects were scheduled for comprehensive eye examinations at the beginning and end of the study. Visual field testing was performed at baseline and 1 week, 4 weeks, 8 weeks, and 1 month or more after discontinuing vigabatrin. Twenty-eight subjects received at least 1 dose of vigabatrin; however, only 20 subjects continued beyond the initial escalating vigabatrin dose phase to the treatment phase. Of these 20 subjects, 18 completed the study with full follow-up. Visual fields were evaluated subjectively by 2 glaucoma specialists and analyzed objectively for group and individual changes in quadrant mean sensitivity. The objective analysis was also repeated for superior field quadrants after excluding the uppermost peripheral points to minimize the eyelid effect. The main outcome measures were change of visual field, visual acuity, and ocular adverse effects. RESULTS: Vigabatrin seemed to help treat cocaine and/or methamphetamine addiction. Of 18 subjects, 16 had negative test results for cocaine and methamphetamine use during the last 6 weeks of the trial. No ocular adverse events were detected. The subjective evaluation did not reveal visual field constriction in any of the 18 evaluable participants. Objective group and individual analyses for quadrant mean sensitivity did not show any change from baseline in any quadrant. No changes in visual acuity were noted. CONCLUSIONS: In this short-term pilot study, vigabatrin seemed to help treat cocaine and/or methamphetamine abuse. There was no evidence of ocular or visual field adverse effects.


Subject(s)
Amphetamine-Related Disorders/drug therapy , Cocaine-Related Disorders/drug therapy , Enzyme Inhibitors/therapeutic use , GABA Agents/therapeutic use , Vigabatrin/therapeutic use , Adult , Amphetamine-Related Disorders/physiopathology , Cocaine-Related Disorders/physiopathology , Enzyme Inhibitors/adverse effects , Female , GABA Agents/adverse effects , Humans , Male , Pilot Projects , Treatment Outcome , Vigabatrin/adverse effects , Visual Field Tests , Visual Fields/drug effects , Visual Fields/physiology
4.
Synapse ; 55(2): 122-5, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15543630

ABSTRACT

This study examined the safety and efficacy of gamma vinyl-GABA (GVG, vigabatrin) for the treatment of methamphetamine and/or cocaine addiction. A total of 30 subjects, who met DSM-IV criteria for methamphetamine and/or cocaine dependence, were enrolled in an open label 9-week safety study. The protocol was specifically designed to include extensive visual field monitoring as well as outcome measures of therapeutic efficacy. Patients were screened twice weekly for the presence of urinary cocaine, methamphetamine, heroin, alcohol, and marijuana. In total, 18/30 subjects completed the study and 16/18 tested negative for methamphetamine and cocaine during the last 6 weeks of the trial. GVG did not produce any visual field defects or alterations in visual acuity. Furthermore, it did not produce changes in vital signs even with continued use of methamphetamine and cocaine. Thus, under conditions that appear to be appropriate for the successful treatment of methamphetamine and/or cocaine addiction, GVG is safe.


Subject(s)
Cocaine-Related Disorders/drug therapy , Enzyme Inhibitors/therapeutic use , Methamphetamine , Substance-Related Disorders/drug therapy , Vigabatrin/therapeutic use , Enzyme Inhibitors/adverse effects , Female , Humans , Male , Treatment Outcome , Vigabatrin/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...